ICON Public Limited Company
ICLRHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. At a $14.29B market cap, ICON Public Limited Company ranks as a large-cap company within healthcare. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Market Cap
$14.29B
Beta
1.24
P/E (TTM)
195.02
P/E (Fwd)
15.74
EPS (TTM)
$0.95
EPS (Fwd)
$11.77
ROE
0.3%
ROA
1.0%
Cash
$928.4M
Total Debt
$3.53B
Free CF
$622.6M
52W Change
1.8%
Annual Financials
Cash vs Debt
Where ICLR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ICLR finished 15.08% above its 150-day moving average ($146.11) and 15.43% above its 200-day moving average ($145.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICLR overbought or oversold?
At the October 20, 2026 close, ICLR's RSI(14) was 47.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $928.4M in cash, though total debt stands at $3.53B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $622.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 0.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $7.74B (2022) to $8.25B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ICON Public Limited Company and its sector.